Opinion | We Cannot Cover These Effective Drugs, Sorry

The article discusses the growing challenge of limited insurance coverage for GLP-1 weight-loss drugs, such as Ozempic, in Massachusetts. Despite their proven effectiveness in reducing risks of chronic diseases, many insurers have restricted or stopped coverage due to high costs, forcing patients to pay out of pocket. This shift raises concerns about equity, as lower-income individuals are disproportionately affected, while some programs like Medicare pilot coverage offer limited relief. The decline in insurance coverage has led to increased reliance on direct-to-consumer companies and telemedicine, reflecting a shift toward market-driven healthcare solutions.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل